Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces

References

• Alhoshani, A., et al., 2020. EGFR inhibitor gefitinib induces cardiotoxicity through the modulation of cardiac PTEN/Akt/FoxO3a pathway and reactive metabolites formation: in vivo and in vitro rat studies. Chemical research in toxicology, 33 (7):1719–1728.
   PubMed Web of Science ®Google Scholar
• Baillie, T.A., 2006. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chemical research in toxicology, 19 (7), 889–893.
   PubMed Web of Science ®Google Scholar
• Ballatore, C., Huryn, D.M., and Smith, A.B., 2013. Carboxylic acid (bio)isosteres in drug design. ChemMedChem, 8 (3), 385–395.
   PubMed Web of Science ®Google Scholar
• Bergman, E., et al., 2007. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. International journal of pharmaceutics, 341 (1–2), 134–142.
   PubMed Web of Science ®Google Scholar
• Cohen, M.H., et al., 2003. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. The oncologist, 8 (4), 303–306.
   PubMed Web of Science ®Google Scholar
• Duckett, D.R. and Cameron, M.D., 2010. Metabolism considerations for kinase inhibitors in cancer treatment. Expert opinion on drug metabolism & toxicology, 6 (10), 1175–1193.
   PubMed Web of Science ®Google Scholar
• Feng, W., et al., 2020. Screening and identification of the main metabolites of schisantherin a in vivo and in vitro by using UHPLC-Q-TOF-MS/MS. Molecules, 25 (2), 258.
   PubMed Web of Science ®Google Scholar
• Fura, A., 2006. Role of pharmacologically active metabolites in drug discovery and development. Drug discovery today, 11 (3–4), 133–142.
   PubMed Web of Science ®Google Scholar
• Guengerich, F.P. and Macdonald, J.S., 2007. Applying mechanisms of chemical toxicity to predict drug safety. Chemical research in toxicology, 20 (3), 344–369.
   PubMed Web of Science ®Google Scholar
• Hirose, T., et al., 2016. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer, 93, 69–76.
   PubMed Web of Science ®Google Scholar
• Kobayashi, H., et al., 2016. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Medical oncology, 33 (6), 57.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2019. Identification of metabolites of eupatorin in vivo and in vitro based on UHPLC-Q-TOF-MS/MS. Molecules, 24 (14), 2658.
   PubMed Web of Science ®Google Scholar
• Li, L., et al., 2020. Metabolite profiling and distribution of militarine in rats using UPLC-Q-TOF-MS/MS. Molecules, 25 (5), 1082.
   PubMed Web of Science ®Google Scholar
• Liu, M., et al., 2013. Characterization and biological effects of di-hydroxylated compounds deriving from the lipoxygenation of ALA. Journal of lipid research, 54 (8), 2083–2094.
   PubMed Web of Science ®Google Scholar
• Liu, R., et al., 2020. Comparative metabolism of schaftoside in healthy and calcium oxalate kidney stone rats by UHPLC-Q-TOF-MS/MS method. Analytical biochemistry, 597, 113673.
   PubMed Web of Science ®Google Scholar
• Liu, X., et al., 2015. Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism. Biochemical pharmacology, 97 (1), 111–121.
   PubMed Web of Science ®Google Scholar
• Mckillop, D., et al., 2006. Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica; the fate of foreign compounds in biological systems, 36 (1), 29–39.
   PubMed Web of Science ®Google Scholar
• Mckillop, D., et al., 2004a. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica, 34 (10), 917–934.
   PubMed Web of Science ®Google Scholar
• Mckillop, D., et al., 2004b. In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems, 34 (11–12), 983–1000.
   PubMed Web of Science ®Google Scholar
• Mckillop, D., et al., 2005. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular cancer therapeutics, 4 (4), 641–649.
   PubMed Web of Science ®Google Scholar
• Pallis, A.G. and Syrigos, K.N., 2013. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung cancer, 80 (2), 120–130.
   PubMed Web of Science ®Google Scholar
• Paz-Ares, L., et al., 2017. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of oncology, 28 (2), 270–277.
   PubMed Web of Science ®Google Scholar
• Pirmohamed, M., 2008. Drug metabolism. Medicine, 36 (7), 355–359.
   Google Scholar
• Rahman, A.F.M.M., Korashy, H.M., and Kassem, M.G., 2014. Gefitinib. In: H.G. Brittain, ed. Profiles of drug substances, excipients and related methodology. Waltham, MA: Academic Press, 239–264.
   Google Scholar
• Swaisland, H., et al., 2001. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clinical pharmacokinetics, 40, 297–306.
   PubMed Web of Science ®Google Scholar
• Yokota, H., et al., 2017. Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clinical lung cancer, 18 (6), e433–e439.
   PubMed Web of Science ®Google Scholar
• Zhang, Z. and Tang, W., 2018. Drug metabolism in drug discovery and development. Acta pharmaceutica sinica. B, 8 (5), 721–732.
   PubMed Web of Science ®Google Scholar
• Zhao, C., et al., 2019. A validated high-performance liquid chromatography-tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: application to a pharmacokinetics study. Biomedical chromatography, 33, e4638.
   PubMed Web of Science ®Google Scholar
• Zheng, N., et al., 2016. Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. Journal of chromatography. B, analytical technologies in the biomedical and life sciences, 1011, 215–222.
   PubMed Web of Science ®Google Scholar